Literature DB >> 35358915

Oncologic outcomes of pathologic T4 and T3 colon cancer patients diagnosed with clinical T4 stage disease using preoperative computed tomography scan.

Seijong Kim1, Jung Wook Huh2, Woo Yong Lee3, Seong Hyeon Yun3, Hee Cheol Kim3, Yong Beom Cho3, Yoon Ah Park3, Jung Kyong Shin3.   

Abstract

BACKGROUND: The diagnostic accuracy of computed tomography (CT) for colon cancer is low, and the preoperative risk factors for locally advanced colon cancer are unknown. This study aimed to evaluate the correlation between preoperative CT scan findings and oncologic outcomes and to identify risk factors associated with locally advanced colon cancer.
MATERIALS AND METHODS: Patients diagnosed with clinical stage (cT) 4 colon cancer based on preoperative CT scan findings who underwent curative surgery between January 2005 and December 2015 were retrospectively studied. Patients were divided according to pathologic stage (pT) into pT3 (n = 114) and pT4 (n = 102).
RESULTS: The disease-free survival rate was significantly different between the pT3 and pT4 groups (88.6% vs. 68.6%, p < 0.001). The overall survival rate of the pT3 group was significantly higher than that of the pT4 group (91.2% vs. 76.5%, p = 0.002). Perineural invasion and tumor budding were identified as preoperative risk factors predisposing to pT4 staging (p = 0.044, p = 0.001).
CONCLUSION: The survival rate of pT3 patients was significantly higher than that of pT4 patients with a preoperative cT4 diagnosis. This suggests that when planning for neoadjuvant chemotherapy in locally advanced colon cancer, preoperative CT scan findings may overestimate clinical staging and lead to inappropriate treatment. Thus, there is a need for a new modality to evaluate local advancement in colon cancer.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical stage; Colon cancer; Diagnosis; Neoadjuvant therapy; Survival

Mesh:

Year:  2022        PMID: 35358915     DOI: 10.1016/j.suronc.2022.101749

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

1.  Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis.

Authors:  Zhujiang Dai; Xiang Peng; Yuegui Guo; Xia Shen; Wenjun Ding; Jihong Fu; Zhonglin Liang; Jinglue Song
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-22       Impact factor: 4.553

2.  Utility of dual-layer spectral-detector CT imaging for predicting pathological tumor stages and histologic grades of colorectal adenocarcinoma.

Authors:  Weicui Chen; Yongsong Ye; Daochun Zhang; Liting Mao; Lei Guo; Hanliang Zhang; Xiaohua Du; Weiwei Deng; Bo Liu; Xian Liu
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.